Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Quick Notes for Sept. 13, 2023

  • Post author:PacConAdmin
  • Post published:September 13, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Our coverage spans relief from third party funded mass tort litigation sought by the medical device industry to Apple prevailing in Masimo patent appeal and two class I device recalls.…

Continue ReadingQuick Notes for Sept. 13, 2023

HHS Responds to Merck’s Lawsuit Over IRA Drug Pricing Provision

  • Post author:PacConAdmin
  • Post published:September 13, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

HHS has petitioned a federal court to toss out a lawsuit from Merck challenging the constitutionality of the Inflation Reduction Act (IRA)’s ability to empower Medicare to negotiate select prices…

Continue ReadingHHS Responds to Merck’s Lawsuit Over IRA Drug Pricing Provision

Jazz Pharma Becomes 25th Drugmaker to Restrict Participation in 340B Program

  • Post author:PacConAdmin
  • Post published:September 13, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Jazz Pharmaceuticals has become the 25th drugmaker to reduce its participation in the controversial 340B Discount Drug Program. Source: Drug Industry Daily

Continue ReadingJazz Pharma Becomes 25th Drugmaker to Restrict Participation in 340B Program

Drug Repackaging Company Safecor Cited in Warning Letter for Mixing Up Drugs

  • Post author:PacConAdmin
  • Post published:September 13, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

A mix up that put a vitamin in a blister pack where a drug to prevent organ transplant rejection belonged is one of several violations the FDA cited in its…

Continue ReadingDrug Repackaging Company Safecor Cited in Warning Letter for Mixing Up Drugs

Selling Drugs, Medical Devices to Iraq is Not an Act of Terrorism, Companies Say

  • Post author:PacConAdmin
  • Post published:September 13, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

The Anti-Terrorism Act (ATA) requires a much higher level of conscious and culpable participation than just selling Iraqi Health Ministry health supplies, AstraZeneca and five other drug and devices makers…

Continue ReadingSelling Drugs, Medical Devices to Iraq is Not an Act of Terrorism, Companies Say

Amgen-Horizon Merger Up for Public Comments Before FTC Will Finalize It

  • Post author:PacConAdmin
  • Post published:September 12, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

The Amgen-Horizon Therapeutics merger isn’t quite over the finish line, because — in accordance with consumer protection and anti-competition laws — the FTC is seeking public comment on the consent…

Continue ReadingAmgen-Horizon Merger Up for Public Comments Before FTC Will Finalize It

Unapproved Eye Drops Earn Drug Makers Eight Warning Letters, Two Import Alerts

  • Post author:PacConAdmin
  • Post published:September 12, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA has issued warning letters to eight companies — including CVS Health and Walgreens Boots Alliance — for manufacturing or marketing illegal, unapproved eye drops to treat pink eye,…

Continue ReadingUnapproved Eye Drops Earn Drug Makers Eight Warning Letters, Two Import Alerts

FDA, FTC Resources Limited for Medical Device Ad Enforcement, Says GAO Report

  • Post author:PacConAdmin
  • Post published:September 12, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

From 2018 to 2022, the FDA took 225 enforcement actions on medical device advertising while the FTC took 67 such actions, says a new report from the Government Accountability Office…

Continue ReadingFDA, FTC Resources Limited for Medical Device Ad Enforcement, Says GAO Report

FDA Seeks Applicants for CDRP Pilot Program

  • Post author:PacConAdmin
  • Post published:September 12, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA has announced the second year opportunity for drugmakers to participate in a Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program to expedite development of products…

Continue ReadingFDA Seeks Applicants for CDRP Pilot Program

Quick Notes for Sept. 12, 2023

  • Post author:PacConAdmin
  • Post published:September 12, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Our coverage spans an Adcomm decision on use of phenylephrine, 1Health.io FTC order for failure to protect privacy and security, user fees for OTC monograph order requests and a GDUFA…

Continue ReadingQuick Notes for Sept. 12, 2023
  • Go to the previous page
  • 1
  • …
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • …
  • 144
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.